Supplementary Material for: Additive Obinutuzumab Achieves High Remission Rates in Rituxim

Supplementary Material for a single-center case series study of 17 patients with rituximab-refractory membranous nephropathy treated with obinutuzumab. The 22.5 KB DOCX file contains clinical and laboratory parameters evaluated before and after treatment, authored by figshare admin karger and last updated in May 2026. The study reports remission rates and immunological response data over a median follow-up of 12.6 months.

Use Cases

• Analyzing remission rates (complete and partial) in a rituximab-refractory patient cohort based on the reported clinical outcomes.
• Studying the correlation between anti-PLA2R antibody levels and treatment response based on the immunological remission data mentioned.
• Benchmarking the efficacy of obinutuzumab against other therapies based on the reported proteinuria and serum albumin levels before and after treatment.

Strengths

• Includes specific clinical metrics for 17 patients, such as proteinuria levels (7.51±3.55 g/d) and anti-PLA2R levels (183.2±92.9 RU/ml).
• Reports detailed remission outcomes, including a 52.9% complete remission rate and a median remission time of 4.4 months.
• Data is shared under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• The dataset is very small (22.5 KB) and the exact row count and column structure are unknown.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

First affiliated hospital of Xi'an Jiaotong university

Collection Method

Single-center case series study evaluating clinical and laboratory parameters.

Time Range

Study period not specified; data reflects a median follow-up of 12.6 months.

Freshness

Last updated 2026-05-22 07:55:18; freshness should be verified.

Geography

Likely China, based on the hospital location.